Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Merck Sharp & Dohme LLC

Chitrananda Abeygunawardana

Luwy Kavuka Musey

Yadong Adam Cui

Michael J Kosinski

Richard J Porambo

Julie Marie Skinner

Jian He

Patrick McHugh

Michael Albert Winters

William J Smith

Joseph G Joyce

Tanaz Petigara

Romulo Ferrero

Kathrin Ute Jansen

John M Williams

Paul M Keller

Emily Wen

James C Cook, Iii

Leslie Cope

Janelle Konietzko

John E MacNair

Charlotte C Ip

Julie M Skinner

Karen M Grimm

Craig T Przysiecki

Robert W Hepler

Keith Roper

Qiuwei Xu

Hari Pujar

Catherine Lancaster

Luwy Musey

Patrick Mchugh

The invention is related to multivalent immunogenic compositions comprising more than onepolysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from anserotype conjugated to a carrier protein, wherein the serotypes ofare as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection againstinfection and diseases caused by. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Compositions comprisingpolysaccharide-protein conjugates and methods of use thereof

The invention is related to multivalent immunogenic compositions comprising more than onepolysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from anserotype conjugated to a carrier protein, wherein the serotypes ofare as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection againstinfection and/or pneumococcal diseases caused by

The present invention provides capsular polysaccharides fromserotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additionalserotypes.

Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates

The invention is related to multivalent immunogenic compositions comprising more than onepolysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from anserotype conjugated to a carrier protein, wherein the serotypes ofare as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection againstinfection and diseases caused by. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

The invention is related to multivalent immunogenic compositions comprising more than onepolysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from anserotype conjugated to a carrier protein, wherein the serotypes ofare as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection againstinfection and/or pneumococcal diseases caused by. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

The present invention provides capsular polysaccharides fromserotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these N serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additionalserotypes.

The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides frombacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.

Enhancing immunogenicity ofpolysaccharide-protein conjugates

A high molecular weight polysaccharide intracellular adhesin (SAE) antigen having the general structure of poly-1,6,&#x3b2;-2-amidoglucopyranoside, which is variable substituted with N-acetyl and O-succinyl substituents is described. Also, a method is given for isolating this antigen from. The SAE can be used in a vaccine, either alone, conjugated to an immunogenic protein, and/or with an immunogenic adjuvant.

[object Object]

Growing community of inventors

Ambler, PA, United States of America

Chitrananda Abeygunawardana